MedTrace Logo

A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.

NCT02135887 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2020-12-22

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled multi-center phaseⅢstudy to evaluate efficacy and safety of oxaliplatin-based chemotherapy plus MB-6(320 mg/capsule, 6 capsules tid) in patients with stage 3 colorectal cancer who underwent surgical excision of their primary tumor.

Conditions

Interventions

DRUG

MB-6

6# TID with meal

DRUG

Placebo

6# TID with meal

Sponsors & Collaborators

  • Microbio Co Ltd

    lead INDUSTRY

Principal Investigators

  • William Chen, M.D. · China Medical University Hospital

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-04
Primary Completion
2022-03-31
Completion
2022-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02135887 on ClinicalTrials.gov